Overview
Psoriatic Immune Response to Tildrakizumab
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-09-01
2025-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of California, San FranciscoCollaborator:
Sun Pharmaceutical Industries LimitedTreatments:
Antibodies, Monoclonal
Criteria
Inclusion Criteria:- 18 years of age or older
- Patients with moderate-severe psoriasis or > 5% body surface area affected.
Exclusion Criteria:
- taking systemic immunosuppressives in the last 4 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- tuberculosis or other active serious infection
- active systemic malignancy.
- breast-feeding
- Presence of a condition or abnormality that in the opinion of the Investigator would
compromise the safety of the patient or the quality of the data.